What changed for Hypertension
A plain English summary of what recently moved in the public data Voxsanity tracks for Hypertension. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 5 to 6 (+1)
- Trials recruiting worldwide 331 to 343 (+12)
- Trials on record 3,499 to 3,627 (+128)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Hypertension in July 2026. Voxsanity tracks 5 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 104 trials tracked for Hypertension that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03298802 · results posted 24 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 400 participants — 201 in the hydrochlorothiazide 50mg tablet group and 199 in the placebo (dummy tablet) group — with 196 in each group completing the study. The trial was looking at what happened to women with high blood pressure in the weeks after giving birth (the period from one to six weeks postpartum). The two main things being measured were: how many participants needed to return to hospital for a visit or urgent assessment, and how many needed extra blood pressure medication during that period. The reported...
-
NCT06764277 · results posted 3 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 people in total who were on dialysis, divided into three groups based on their average blood pressure readings: 15 people in Group A (blood pressure below 130/80), 7 people in Group B (blood pressure between 130–139/80–89), and 10 people in Group C (blood pressure at or above 140/90). All 32 participants completed the study. The trial was measuring several things related to how the heart and blood vessels were functioning between dialysis sessions, as well as certain substances in the blood that can affect blood pr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06017102 · results posted 23 January 2026
According to the results reported on ClinicalTrials.gov, this trial compared two types of stomach examination procedures in 50 adults — 25 people underwent a standard upper endoscopy (called esophagogastroduodenoscopy, or EGD, where a flexible tube with a camera is passed down the throat) and 25 people underwent a newer approach called Wired Magnetic Assisted Capsule Endoscopy (WMACE, where a small swallowable camera capsule is guided by a magnet). All 50 participants completed the trial. The main thing the trial was measuring was the amount of tiny airborne particles (aerosols) produced durin...
-
NCT05562934 · results posted 24 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05562934) enrolled 189 adults across five groups to test different doses of a medicine called XXB750 against a placebo (a dummy treatment with no active ingredient) for high blood pressure. The groups received either placebo or one of four doses of XXB750: 30 mg, 60 mg, 120 mg, or a higher dose of 120 mg/240 mg. The main thing the trial was measuring was the change in 24-hour ambulatory systolic blood pressure (the "top number" in a blood pressure reading, averaged over a full day using a monitoring device) after 12 weeks...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03733145 · results posted 24 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 people in total across three groups, all of whom had high blood pressure (hypertension) and were already taking blood pressure-lowering medication. Ten were taking a type of medication called ACE inhibitors, eleven were taking a type called ARBs (angiotensin receptor blockers), and eleven were on other types of blood pressure medication. The trial was measuring how much of a substance called angiotensin II (a natural hormone that can raise blood pressure) was needed to bring each person's blood pressure back up to...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05800145 · results posted 5 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 participants across six groups, each receiving a different combination of support: information and resource referrals only, support from a Community Health Worker (CHW — a trained local health support person), medically tailored meals (MTM — meals designed to suit specific health conditions), or combinations of these. The trial was designed to test whether these approaches were practical to run (for example, how many people agreed to join and stayed until the end), and also to track participants' blood pressure rea...
-
NCT02373163 · results posted 29 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 166 people across three groups, each receiving a different type of blood pressure medication: a diuretic (a fluid-removing tablet), a calcium-channel blocker, or an angiotensin receptor blocker. There were 56 people in the diuretic group and 55 in each of the other two groups. All participants completed the study — none dropped out. The trial was measuring how much each medication changed blood pressure and related measures over a 24-hour period, comparing readings taken at the start of the study to readings taken aft...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05928624 · results posted 22 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 69 people in total — 34 in a standard care group and 35 in a group that used home blood pressure monitors and scales to help guide their clinical care. All 69 participants completed the study with no dropouts reported. The trial was looking at two things: changes in a measure called mean arterial pressure (a way of calculating the average pressure in the blood vessels during a heartbeat cycle), and changes in the burden of fluid build-up in the abdomen (known as ascites), measured by how much fluid was drained over th...
-
NCT05161481 · results posted 15 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05161481) enrolled 80 people in total — 26 in the placebo group, 27 in the avenciguat 2 mg twice-daily group, and 27 in the avenciguat 3 mg twice-daily group. The trial was measuring changes in a reading called the Hepatic Venous Pressure Gradient (HVPG) — a measure of pressure inside the liver's blood vessels, taken via a specialised procedure. The study ran for 24 weeks and was testing whether avenciguat, at two different doses, changed that pressure reading compared to a dummy treatment (placebo). The reported data sho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05401409 · results posted 8 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people in total — 30 in each group. Participants were randomly assigned to drink either nitrate-rich beetroot juice or nitrate-depleted beetroot juice (a comparison drink with the nitrates removed) every day for four weeks. The trial was measuring changes in blood pressure, as well as several markers in blood and urine that relate to how blood vessels function. One person in the nitrate-rich group did not complete the study; everyone in the nitrate-depleted group finished. The reported data shows that both groups...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03557502 · results posted 4 June 2025
According to the results reported on ClinicalTrials.gov, this trial compared two groups of people: one group received heat therapy and the other did aerobic exercise. In the first part of the study (Protocol 1), 21 people started and completed the heat therapy group, and 20 started and completed the aerobic exercise group. In the second part (Protocol 2), 17 heat therapy participants and 14 aerobic exercise participants started, with 15 and 12 respectively completing it. The trial was measuring changes in blood pressure and arterial stiffness (a measure of how flexible the blood vessels are) a...
-
NCT04518306 · results posted 3 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04518306) tested two different dose strengths of a combination blood pressure pill called GMRx2 — one at a lower dose (called "Triple ¼") and one at a higher dose (called "Triple ½") — against a placebo (a dummy pill with no active ingredients). The trial first ran a lead-in phase where 755 people took a placebo, and 295 of those went on to the main comparison phase. In that main phase, 113 people were assigned to the lower-dose GMRx2, 119 to the higher-dose GMRx2, and 63 to placebo. The trial measured changes in blood pre...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04518293 · results posted 3 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04518293) looked at blood pressure readings in people with high blood pressure. The trial compared a triple-combination treatment called GMRx2 (three blood pressure medicines in one pill) against three different two-medicine combinations: one called Dual-TA, one called Dual-TI, and one called Dual-AI. The trial began with a run-in phase where 2,244 people took a single active treatment for four weeks; 1,385 completed that phase. From there, 1,385 people moved into the main double-blind phase (where neither participants nor...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06104423 · results posted 24 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06104423) involved people with high blood pressure that was not well controlled on a single blood pressure medicine. In the first stage, 128 people took nebivolol 5 mg and 138 people took ramipril 5 mg on their own for about four weeks. Those who did not reach their blood pressure target then moved into the second stage, where 255 people took a combination of both medicines (nebivolol 5 mg together with one of three doses of ramipril: 2.5 mg, 5 mg, or 10 mg) for 12 weeks. The trial's main goal was to measure how much sitti...
-
NCT02235909 · results posted 25 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02235909) involved multiple phases and several hundred participants across different treatment groups. In the first (double-blind) phase, 215 people were enrolled across four groups — one receiving a comparison medication called losartan, three receiving different doses of azilsartan medoxomil (AZM), and a placebo group was used in a later withdrawal phase. In the withdrawal phase, 203 people took part, and in a final open-label phase, 197 people participated. The trial was measuring changes in blood pressure readings — sp...
-
NCT05765253 · results posted 11 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05765253) enrolled a total of three people. Two participants underwent a procedure called TIPS (a type of internal shunt created in the liver to redirect blood flow) using a device called the Scorpion Portal Vein Access Kit, while one participant had the same procedure performed using a Cook Transjugular Liver Access Set. The trial was measuring whether the procedure could be completed successfully and whether any serious complications occurred, as well as tracking how long different steps of the procedure took and how man...
-
NCT04790279 · results posted 28 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 175 people in total — 87 in the Amlodipine group and 88 in the Nifedipine ER (extended-release) group. The trial was comparing these two blood pressure medicines in people who had given birth, looking at how long they stayed in hospital after delivery, how often they needed extra (acute) blood pressure treatments, any side effects they experienced, and a number of other outcomes including hospital readmissions and breastfeeding duration. Not everyone completed the trial — 51 of the 87 people in the Amlodipine group an...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03503773 · results posted 4 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03503773) enrolled 106 people in total — 56 in a sham (inactive/pretend procedure) control group and 50 in the treatment group. The trial was measuring changes in blood pressure, specifically looking at readings taken over a full 24-hour period using a monitoring device worn by participants, as well as standard clinic readings taken by a doctor or nurse. Not everyone finished the study: 44 people completed it in the sham group and 43 in the treatment group. The reported data shows that for the main outcome — the change in...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04442464 · results posted 29 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04442464) enrolled just one participant, whose two eyes were each treated differently — one eye was designated the "Study Eye" and the other the "Control Eye." The trial was measuring intraocular pressure (IOP), which is the pressure inside the eye, recorded in millimetres of mercury (mmHg). This is a measurement commonly used when monitoring eye health conditions such as glaucoma. The reported data shows two sets of pressure readings for each eye, likely taken at different points in time. For the Study Eye, the reported...
-
NCT05347147 · results posted 24 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05347147) tested a treatment called Presendin against a placebo (an inactive dummy treatment) in people with raised pressure inside the skull — a condition sometimes called intracranial hypertension. The main thing the trial was measuring was the change in that pressure over 24 weeks, checked by a procedure called a lumbar puncture (a needle inserted into the lower back to measure the pressure of the fluid around the brain and spinal cord). The trial also tracked vision, swelling at the back of the eye (called papilloedema...
-
NCT02577835 · results posted 1 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02577835) enrolled 1,342 people with high blood pressure (hypertension), of whom 1,200 completed the study and 142 did not finish. The trial was an observational study — meaning it watched and measured participants rather than testing a new treatment. It focused on measuring artery stiffness and blood pressure readings taken over a full 24-hour period, using specialised techniques that look at how blood pressure behaves throughout the day and night, including at the level of the main central artery (the aorta). The report...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04603560 · results posted 28 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04603560) involved 511 people in total — made up of patients and their healthcare providers. Patients were split into three groups: one group received a "social norming" intervention (which involves sharing information about what most people in a similar situation do), one group received a "pharmacist e-detailing" intervention (where a pharmacist provided information electronically to the treating doctor), and one control group that did not receive either intervention. There were also small groups of healthcare providers a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01911897 · results posted 22 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT01911897) enrolled 30 people, all of whom received a device called the MobiusHD. The trial was looking at serious unwanted medical events (called serious adverse events) as its main focus, and also tracked blood pressure readings taken in a clinic and over a 24-hour period as secondary measures. Of the 30 people who started, 27 completed the study and 3 did not. The reported data shows that 8 out of 30 participants experienced at least one serious adverse event during the study. For the clinic-based blood pressure reading...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02570113 · results posted 28 September 2023
According to the results reported on ClinicalTrials.gov, this trial involved 45 people who all received a procedure called renal denervation by neurolysis — a technique aimed at disrupting certain nerves near the kidneys that are thought to play a role in blood pressure. Of the 45 who started, 42 completed the study. The trial was measuring two main things: whether certain serious complications were absent in the month following the procedure, and whether participants' blood pressure (measured over 24 hours using a monitoring device) changed over six months. The reported data shows that 43 ou...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05137002 · results posted 1 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT05137002) was conducted in two parts and looked at a medication called CIN-107 in people with uncontrolled high blood pressure. In Part I (8 weeks), 249 people were enrolled across four groups — one receiving a placebo (a dummy treatment with no active ingredient) and three receiving different doses of CIN-107 (0.5 mg, 1 mg, or 2 mg). Around 227 of those participants completed Part I. In Part II (4 weeks), a separate group of 213 people all received the 2 mg dose of CIN-107, with 201 completing that phase. The trial measur...
-
NCT04914819 · results posted 6 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04914819) enrolled 60 people in total — 40 were placed in an online behavioural weight loss programme and 20 received usual care. The trial was looking at several things at once: how well different recruitment strategies (emails and mailed letters) brought people in, how weight changed over 16 weeks, and how many people completed the study. Of the 40 in the programme group, 26 finished all follow-up steps, while 18 out of 20 in the usual care group did so. The reported data shows that, on average, people in the online pro...
-
NCT04742283 · results posted 26 January 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04742283) enrolled 323 people in total — 161 in one group and 162 in another. One group used Timolol Maleate eye drops (0.5%) twice a day, while the other used DE-126 eye drops (0.002%) once a day along with a plain vehicle (inactive) drop. The trial was measuring the pressure inside the eye — known as intraocular pressure, or IOP — which is simply the fluid pressure within the eyeball. This was checked at three different times during the day at several points: two weeks, six weeks, and three months into the trial. Most pa...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03959592 · results posted 3 January 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03959592) enrolled a total of 8 participants — 3 in the group receiving a combination of lutein, zeaxanthin, and mesozeaxanthin (three natural pigments found in the eye), and 5 in the placebo group (a dummy treatment with no active ingredients). All 8 participants completed the study. The trial was measuring several aspects of vision, including contrast sensitivity (the ability to notice subtle differences in shading and patterns), the density of pigment in the central part of the retina, vision in glare, visual field, dar...
-
NCT02922023 · results posted 2 December 2022
According to the results reported on ClinicalTrials.gov, this trial was designed to look at two approaches to managing blood pressure — one called "chronotherapy" (timing when blood pressure medication is taken) and another using ambulatory blood pressure monitoring (ABPM, which involves wearing a blood pressure monitor over a period of time). The trial aimed to measure changes in blood pressure after one month of adjusted medication, and how many participants in each group reached their blood pressure goal. The reported data shows that only 2 participants were enrolled in the chronotherapy g...
-
NCT04465630 · results posted 7 June 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 78 people who had a specific combination of eye conditions — they had previously had cataract surgery (making them "pseudophakic") and also had open-angle glaucoma, a condition involving pressure build-up in the eye. The trial was measuring changes in eye pressure and changes in the number of eye-pressure-lowering medications participants were using, looking at results up to six months after a procedure. It is worth noting that the data shows zero participants were recorded as having formally "completed" the study, as...
See all 104 reported results for Hypertension
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, hypertension is receiving a very large amount of public research investment from the United States government, and that level of support has remained broadly steady over recent years. For patients, this signals that hypertension is a well-established research priority, with a sustained commitment to understanding and addressing the condition. This kind of consistent,...
See the full Hypertension page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.